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Abstract
Background: The aim of the study is to investigate the clinical features, treatments, and prognosis of stage 1
embryonal rhabdomyosarcoma of the female genital tract.
Methods: A retrospective analysis was performed on nine cases of stage 1 embryonal rhabdomyosarcoma of the
female genital tract. Clinical characteristics, treatments, recurrence, and prognosis were analyzed.
Results: Of the nine patients with embryonal rhabdomyosarcoma, three originated from the vagina and six from
the cervix. For the eight patients who initially received surgery, the median survival time was 88 months. As for
the six patients that received adjuvant chemotherapy, five of them who received six or more cycles of treatment
achieved tumor-free survival and the survival time ranged from 9 to 228 months. The remaining patient, who
declined further treatment after two cycles of chemotherapy, relapsed 11 months following the surgery and died
3 months later. Out of the nine patients, only one was initially treated with chemotherapy, and achieved
complete remission, but relapsed 21 months later. After a combination of surgery and chemotherapy, this patient
remained tumor-free for total of 117 months.
Conclusions: Patients with early stage embryonal rhabdomyosarcoma of the female genital tract have good
prognosis, and the combination of surgery and chemotherapy can lead to better outcomes.
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Background
Rhabdomyosarcoma is a rare tumor that occurs mostly
in children and adolescents, and rarely in adults, and
represents 2–5% of all soft tissue sarcomas [1]. Approxi-
mately two-thirds of the cases are diagnosed in children
younger than 6 years of age.
Rhabdomyosarcomas (RMS) is divided into three
pathological subtypes including embryonal (ERMS),
alveolar (ARMS), and pleomorphic rhabdomyosarco-
mas (PRMS) [2, 3], of which the ERMS and ARMS are
the most common subtypes in children and adoles-
cents [1, 4, 5]. PRMS is mainly found in adults with
the incidence increasing with age [6].
ERMS mostly occurs in the head and neck regions,
whereas PRMS is mostly found in the limbs and trunk [7].
In adults, PRMS is more common than other subtypes [4]
and its clinical and biological behaviors are closer to
high-grade soft tissue sarcomas. The Intergroup of
Rhabdomyosarcoma Study Group (IRSG) founded in
1972 has developed a surgical-pathologic grouping sys-
tem [8, 9], followed by a pre-treatment clinical staging
system [10], and is currently widely used by most
scholars.
Rhabdomyosarcoma of the female genital tract is most
common in infants, children, and adolescents. Given the
rareness of rhabdomyosarcoma of the female genital
tract, currently, no standard treatment is available, and
recommended strategies are mostly based on treatments
for rhabdomyosarcoma of other sites. Here, we per-
formed a retrospective analysis on nine cases of stage 1
embryonal rhabdomyosarcoma of the female genital
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tract admitted in the Cancer Hospital of Chinese Acad-
emy of Medical Science. The clinical manifestations,
treatments, and prognosis were analyzed, aiming to pro-




A total of nine cases of stage 1 embryonal rhabdomyosar-
coma of the female genital tract, admitted in our hospital
from January 1975 to December 2014, were analyzed.
The ethics committee of the Cancer Hospital of
Chinese Academy of Medical Science approved this
retrospective study. All the patients’ records were
anonymized and de-identified prior to analysis. There-
fore, informed consent was not obtained from the
patients.
Medical records of the nine patients were reviewed,
and their clinical characteristics, treatments, recurrence,
and prognosis were analyzed retrospectively.
All cases with embryonal rhabdomyosarcoma were
followed up by phone or mail. The cutoff date of the
follow-up was April 1, 2015.
Statistical analysis
Data were analyzed with SPSS 19.0 statistical software.
Results
General clinical features
Of the nine patients, three cases of ERMS primarily oc-
curred in the vagina and six cases occurred in the cervix.
The age ranged from 6 to 37 years, and the median age
was 21 years. According to the IRSG staging system, all
cases were classified as stage 1. In all three cases of
rhabdomyosarcoma of the vagina, a vaginal mass was
the initial manifestation, and the longest tumor diameter
ranged from 1 to 6 cm. According to the 2012 Inter-
national Federation of Gynecology and Obstetrics sta-
ging system, two cases were classified as stage I and 1
case as stage II. Of the six cases of rhabdomyosarcoma
of the cervix, five patients initially presented with vaginal
bleeding and one presented with increased vaginal dis-
charge. The longest tumor diameter ranged from 0.5 to
12 cm, and according to 2012 FIGO staging system,
three cases were classified as stage I, two cases as stage
II, and one case as stage III (Table 1).
Treatment approaches and prognosis
As of nine patients, eight initially received surgery, and
one received just chemotherapy regimen of cyclophos-
phamide + vincristine + actinomycin for 12 cycles. The
patient that received only chemotherapy achieved
complete remission but relapsed 21 months after the
end of the chemotherapy. After receiving surgery and
the postoperative adjuvant chemotherapy, the patient
has maintained tumor-free for a total of 117 months so
far.
Of the eight patients who initially received surgery
with a median survival time of 88 months (9–
228 months), six patients received adjuvant chemother-
apy, one of whom also received adjuvant external beam
radiotherapy. Of the six patients, five patients who
completed ≥6 cycles of chemotherapy all survived
tumor-free until the cutoff date of the follow-up (sur-
vival time range, 9~228 months). The other patient
only received two cycles of postoperative chemotherapy
(dactinomycin + vincristine + cyclophosphamide) be-
fore abandoning treatment voluntarily. Recurrent can-
cer of the vaginal stump accompanied by brain and
lung metastases was found in the patient 11 months
after the surgery. The patient then received palliative
treatments and died 3 months later, with an overall
Table 1 Stage, treatment, and prognosis of embryonal rhabdomyosarcoma of the female genital tract
No. Age
(years)


















1 17 Vagina 1.0 I 1 I Low, subset A S C Dead 25.0
2 6 Vagina 4.9 I 1 III Low, subset B C S+C NED 117.0
3 34 Vagina 6.0 II 1 I Low, subset A S N NED 15.0
4 36 Cervix 5.7 IIIA 1 I Low, subset A NC+S+C N NED 9.0
5 20 Cervix 12.0 IIA2 1 I Low, subset A S+C N NED 153.0
6 37 Cervix 2.0 IB1 1 I Low, subset A S+Cb P Dead 14.0
7 21 Cervix 0.5 IB1 1 I Low, subset A S+C N NED 151.0
8 21 Cervix 10.5 IIA2 1 I Low, subset A S+C N NED 228.0
9 23 Cervix 4.5 IB2 1 I Low, subset A S+C+R N NED 198.0
IRSG Intergroup Rhabdomyosarcom Study Group, S surgery, C chemotherapy, NC neoadjuvant chemotherapy, R radiotherapy, P palliative treatment, N without
recurrence, NED no evidence of disease
aThe cutoff date of the follow-up was April 1, 2015
bOnly received two courses of chemotehrapy
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survival time of 14 months. As for the two patients
who did not receive postoperative adjuvant therapies,
one has a disease-free survival of 15 months so far,
while the other patient had abdominal tumor recur-
rence 24 months after the surgery. Due to the inoper-
able condition, the patient received one cycle of
chemotherapy and died a month later with an overall
survival time of 25 months.
Due to the great time span (40 years) in which these
patients received treatments, although all patients were
given combination chemotherapies, specific chemo-
therapy regimens varied. The earliest case received a
regimen containing cyclophosphamide and hydroxy-
urea in 1975. Later, three patients received regimens
using triazene melamine, etoposide, or ifosfamide com-
bined with adriamycin and cisplatin, respectively, one
patient received paclitaxel, ifosfamide, and cisplatin,
and two patients received a regime containing vincris-
tine, actinomycin, and cyclophosphamide.
Survival time and prognosis
Until the cutoff day of the follow-up, the follow-up dur-
ation was from 9 to 228 months, with a median duration
of 117 months (range 9~228 months). Nine cases were
identified, two were already dead, and the remaining
seven were followed up. Seven achieved tumor-free sur-
vival with a median survival time of 151 months, two pa-
tients died with a survived time of 14 months and
25 months, respectively. The median survival time of the
nine patients was 117 months (9~228 months).
Discussion
The diagnosis of rhabdomyosarcoma mainly depends on
the pathological examination of biopsies combined with
imaging exams [11]. The 3-year progression-free survival
rates of IRSG groups I, II, and III patients are 83, 86,
and 73%, respectively (p < 0.001) [12], and the long-term
survival rate of group IV RMS patients is less than 30%
[13, 14]. The 3-year progression-free survival rates of
stages 1, 2, and 3 are 86, 80, and 68%, respectively (p <
0.001) [12]. Currently, IRSG, now called the Children’s
Oncology Group (COG) Soft Tissue Sarcoma Commit-
tee, is conducting multiple clinical studies related to
RMS.
At present, the multimodal therapy, consisting of
chemotherapy and surgery, with or without radiother-
apy, has become the recommended treatment for RMS
[15]. Using this treatment approach, RMS survival rate
has increases from 25% in the 1970s to 71% in the 1990s
[8, 10, 12, 16]. Now, COG combines the risk rating and
the staging to divide pediatric patients with RMS into
low-risk, intermediate-risk, and high-risk groups [8].
The 3-year progression-free survival rates of low-risk,
intermediate-risk, and high-risk groups are 88, 55–76,
and <30%, respectively. Due to the good prognosis of pa-
tients in the low-risk group, studies are currently trying
to reduce the intensity of treatment and thereby alleviate
treatment-related complications. The survival rate of
adolescent and adult patients with RMS (21–56%) is sig-
nificantly lower than that of children, and several studies
are trying to improve its prognosis [15, 17].
The nine patients in this report were all classified as
stage 1 according to IRSG staging system, and their me-
dian survival time was 117 months (ranged from 9 to
228 months). There were a total of seven cases that
achieved disease-free survival, of which five were treated
with surgery and postoperative chemotherapy, and one
initially received the chemotherapy regimen including
vincristine, dactinomycin, and cyclophosphamide, and
achieved complete remission, but followed by tumor re-
lapse 21 months later. The patient was then treated with
surgery and chemotherapy and has remained tumor-free
until now. Another patient, although only received sur-
gery, also has survived tumor-free for 15 months (a
shorter follow-up).
As of the two patients who did not survive, one did
not receive chemotherapy, and the tumor recurred in
the pelvic and abdominal cavities 24 months after the
surgery, which caused the death of the patient 1 month
later. The other patient only underwent two cycles of
postoperative chemotherapy before abandoning treat-
ment voluntarily, and the vaginal stump recurrence and
lung metastasis were found 9 months later. The patient
was subsequently treated with palliative cares and died
3 months later with an overall survival time of
14 months. Therefore, for female patients with stage 1
ERMS, surgical treatment combined with 6 cycles of
adjuvant chemotherapy may be necessary to improve
survival, and patients that undergo insufficient postop-
erative chemotherapy are susceptible to a high risk of
recurrence.
In this group of patients, only two were younger than
18 years old, and the rest were over 20 years old, which
is inconsistent with the previously reported age distribu-
tion of ERMS, possibly due to the majority of pediatric
patients being treated in Children’s Hospitals in China.
So, most patients admitted at our hospital were adults,
resulting in different age distributions.
Specifically for children with RMS, the IRS-III study
had used a chemotherapy regimen containing vincristine
and dactinomycin (VA), which resulted in 83 and 70% 5-
year tumor-free survival rates in the low-risk sub-group
A and subgroup B, respectively, while the IRS-IV study
had used a chemotherapy regimen containing vincris-
tine, dactinomycin, and cyclophosphamide (VAC), which
resulted in 93 and 84% 5-year disease-free survival rates,
respectively [10, 12]. Although, the addition of cyclo-
phosphamide improved survival, the occurrence of
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complications including myelosuppression, infection and
infertility, increased [18].
Currently, VAC (vincristine, dactinomycin, and cyclo-
phosphamide) chemotherapy is the standard regimen for
children with non-metastatic RMS (moderate-risk or
high-risk groups) [19]. A randomized controlled trial
(D9803) conducted by COG has compared the efficacy
between VAC chemotherapy and the combination of
vincristine, topotecan, and cyclophosphamide in patients
with moderate-risk RMS, and the results demonstrated
73 and 68% 4-year progression-free survival rates, re-
spectively (p = 0.30), indicating that topotecan does not
yield superior results over dactinomycin [19].
Since RMS is very rare in adults, selection of chemo-
therapeutic drugs is mostly based on the outcomes in
pediatric patients.
Due to the long time span of this study, the patients
received different chemotherapeutic drugs including
sarcoma-effective vincristine, doxorubicin, cisplatin, tria-
zene melamine, ifosfamide, and cyclophosphamide. Out
of the nine patients, two had received COG recom-
mended VAC (cyclophosphamide, vincristine, and acti-
nomycin). Despite different chemotherapy regimens,
those patients that completed more than 6 cycles of
chemotherapy showed good prognosis, indicating that in
addition to the COG recommended chemotherapy,
other drugs may be effective for embryonal rhabdomyo-
sarcoma and worth further investigations. COG is now
conducting a number of relevant clinical trials.
The surgical treatments for RMS are site-specific,
and tumors should be removed as completely as pos-
sible. The level of completeness of the surgical resec-
tion directly affects the prognosis. However, if the
surgery would cause a significant dysfunction or im-
pact appearance (such as RMS of the head, neck, and
genital tract), radical surgery is not recommended, but
instead, palliative resection or radiotherapy combined
with chemotherapy can be used. In this report, of the
three patients with vaginal rhabdomyosarcoma, two pa-
tients who underwent surgery both received extended
local resection, which resulted in one death with a sur-
vival time of 25 months, and one tumor-free survival
for 15 months at the end of the study. All six cases of
cervical rhabdomyosarcoma received surgery, of whom
three underwent hysterectomy. One of these patients,
due to the incomplete course of chemotherapy, had re-
currence and died later with an overall survival time of
14 months, and the other two survived tumor-free for
151 months and 153 months, respectively. The
remaining three patients with cervical rhabdomyosar-
coma underwent radical hysterectomy and remained
tumor-free for 9, 198, and 228 months, respectively.
These results indicate that extended local resection is
good enough for vaginal RMS, while for cervical
rhabdomyosarcoma, hysterectomy yields better out-
comes. Given the young age of these patients, fertility
preservation was a major concern. In recent years, pa-
tients whose fertility was preserved have been reported
[20, 21]. Dehner reported 14 cases with embryonal
rhabdomyosarcoma confined to the cervix (aged from
9 months to 32 years) [20], among which 12 patients
were found with polypoid tumors, one with cervical
nodular masses, and one with a tumor inside the cer-
vical canal. Of the 14 patients, 13 underwent tumorect-
omy and following the pathological diagnosis of
rhabdomyosarcoma, the patients were further treated
with a loop electrosurgical excision procedure or cer-
vical conization. For the patient with cervical nodular
masses, following tumorectomy, a radical hysterectomy
was performed. All patients received postoperative ad-
juvant chemotherapy. Of the 13 patients who received
local surgical treatment, one was lost to follow-up
1 year later and one patient relapsed 1 year after the
end of the treatment and was lost to follow-up later.
Two patients were found to have pulmonary metastasis
2 and 3 years after the treatment, respectively, but
survived tumor-free following local excisions. The
remaining eight patients were followed up for 2 to
20 years, and all of them achieved tumor-free survival.
The patient who had received radical hysterectomy had
recurrence in the pelvic cavity 3 years later but was
alive with tumor.
Kriseman analyzed 11 cases of cervical embryonal
rhabdomyosarcoma retrospectively [21], among which,
according to the FIGO staging system, four were classi-
fied as stage IB1, four as stage IB2, one as stage IIA, and
two as stage unknown. Of the 11 patients, eight patients
underwent cervical conization or cervical tumorectomy,
and all patients received postoperative adjuvant chemo-
therapy (seven cases received VAC, one case received a
combination chemotherapy containing doxorubicin,
cyclophosphamide, and vincristine). The median follow-
up of the patients was 23 months. There were two
patients who had recurrence, one of which died of neu-
tropenia following chemotherapy and the other one was
alive with tumor (the survival time was not reported).
The remaining six patients survived tumor-free for 4–
35 months. The authors recommend that for treating
patients with an early stage cervical rhabdomyosarcoma,
a local excision combined with the postoperative chemo-
therapy should be considered. However, since the num-
ber of cases in these studies is small and the studies are
all retrospective, whether or not local excision is an
appropriate approach remains to be confirmed.
Radiotherapy is an important component of the com-
prehensive treatment of pediatric RMS. For patients with
tumors that cannot be surgically removed, or with re-
sidual tumors or lymph node involvement (IRS groups
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II, III, and IV), induction chemotherapy followed by
concurrent chemoradiotherapy is currently the recom-
mended therapeutic modality [22]. In this report, only
one received postoperative adjuvant radiotherapy, which
was used in combination with the chemotherapy. The
patient has survived for 198 months, which is higher
than the median survival time of the five patients who
received a combination of surgery and chemotherapy.
Conclusions
The prognosis of early stage embryonal rhabdomyosar-
coma of female genital tract is good, and its standard
therapeutic modality is the combination of surgery and
chemotherapy. Currently, the standard chemotherapy that
IRSG (2001) recommends comprises of vincristine, dacti-
nomycin, and cyclophosphamide [12, 19]. For the surgical
treatment of vaginal rhabdomyosarcoma, extended
local resection has shown better outcome. For cervical
rhabdomyosarcoma, whether fertility-preserving surgi-
cal approaches should be adopted requires further
investigation.
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